Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Oncol., 13 August 2025

Sec. Cancer Immunity and Immunotherapy

Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1645247

This article is part of the Research TopicInnovative Therapeutic Approaches for Complex Cancers: Exploring New StrategiesView all 12 articles

Correction: Enhanced anti−tumor efficacy of “IL−15 and CCL19” −secreting CAR−T cells in human glioblastoma orthotopic xenograft model

This article is a correction to:

  1. Enhanced anti-tumor efficacy of "IL-15 and CCL19" -secreting CAR-T cells in human glioblastoma orthotopic xenograft model

    1. Read original article
Wanqiong Chen&#x;Wanqiong Chen1†Limian Hong&#x;Limian Hong2†Shaomei Lin&#x;Shaomei Lin1†Na Xian,Na Xian3,4Cailing YanCailing Yan5Ningning ZhaoNingning Zhao6Yonglei XiaoYonglei Xiao3Wanting LiaoWanting Liao1Yuxiang HuangYuxiang Huang1Mingzhu Chen*Mingzhu Chen1*
  • 1School of Pharmacy, Quanzhou Medical College, Quanzhou, Fujian, China
  • 2Department of Pharmacy, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian, China
  • 3Institute of Immunotherapy, Fujian Medical University, Fuzhou, Fujian, China
  • 4Tcelltech Biological Science and Technology Inc., Fuzhou, Fujian, China
  • 5Public Technology Service Center, Fujian Medical University, Fuzhou, Fujian, China
  • 6Laboratory Animal Center, Fujian Medical University, Fuzhou, Fujian, China

A Correction on
Enhanced anti−tumor efficacy of “IL−15 and CCL19” −secreting CAR−T cells in human glioblastoma orthotopic xenograft model

By Chen W, Hong L, Lin S, Xian N, Yan C, Zhao N, Xiao Y, Liao W, Huang Y and Chen M (2025). Front. Oncol. 15:1539055. doi: 10.3389/fonc.2025.1539055

In the published article, there was an error in Figure 4B as published. During figure compilation, the image intended to represent the first mouse in the UTD group was erroneously placed as the third mouse in the EGFRvIII CAR group on day 7 post-tumor-cell injection, resulting in image duplication in Figure 4B. This was an unintentional error in image placement. The corrected Figure 4 and its caption appear below.

Figure 4
Bioluminescence images of mice in three groups: UTD, EGFRvIII CAR, and 15×19 EGFRvIII CAR, taken on days 7, 11, 16, 23, 30, and 37 post-tumor injection. Brightly colored areas indicate tumor presence and activity, with intensity shown in a color scale ranging from blue (low) to red (high) luminescence. Tumor activity diminishes over time in both EGFRvIII CAR and 15×19 EGFRvIII CAR groups, particularly reduced in 15×19 EGFRvIII CAR group.

Figure 4. Anti-tumor effects of 15 × 19 EGFRvIII CAR-T cells in human GBM orthotopic xenograft models. (A) Schematic representation of the in vivo anti-tumor experiment. NCG mice were intracranially injected with EGFRvIII+ U87 MG-Luc cells and subsequently treated with intravenous injections (i.v) of CAR-T cells or UTD T cells (n = 4). (B) Assessment of tumor growth using the IVIS system at different time points. (C) Calculations of total flux (p/s) using Living Image software at different time points. (D) Calculation of total flux (p/s) in the CAR-T cells group on day 16. Error bars denote SEM, *P<0.05. (E) The percentage survival per group was determined and is represented in a Kaplan–Meier survival curve.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: CAR-T cells, glioblastoma, IL-15, CCL19, cancer immunotherapy, EGFR vIII

Citation: Chen W, Hong L, Lin S, Xian N, Yan C, Zhao N, Xiao Y, Liao W, Huang Y and Chen M (2025) Correction: Enhanced anti−tumor efficacy of “IL−15 and CCL19” −secreting CAR−T cells in human glioblastoma orthotopic xenograft model. Front. Oncol. 15:1645247. doi: 10.3389/fonc.2025.1645247

Received: 11 June 2025; Accepted: 24 July 2025;
Published: 13 August 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Chen, Hong, Lin, Xian, Yan, Zhao, Xiao, Liao, Huang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Mingzhu Chen, MjAwODAyNUBxem1jLmVkdS5jbg==

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.